Rare diseases
Investigational molecules
Locations
Ul. Wawelska 15, 02-034 Warsaw, Poland
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy in Warsaw, Poland specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer, Non-small cell lung cancer metastatic, Malignant melanoma, and other specialisations. This site conducts important research.
The Narodowy Instytut Onkologii Im. Marii Sklodowskiej‑Curie‑Panstwowy Instytut Badawczy in Warsaw is conducting a series of trials focused on Hepatocellular Carcinoma, exploring new combination therapy approaches to improve response rates and survival outcomes.
Across 11 trials, 55 investigators are collaborating to bring innovative liver cancer therapies to patients in Europe.
Research at the institute includes targeted investigations of Microsatellite Instability‑High and KRAS mutant metastatic colorectal cancer, testing novel agents and personalized treatment strategies.
The program emphasizes personalized medicine and collaborates with leading European oncology networks.
The site is advancing immune checkpoint inhibitor research by evaluating combinations such as relatlimab with nivolumab and triple‑agent regimens that include atezolizumab, bevacizumab, and tiragolumab.
These efforts reflect a commitment to expanding immunotherapy options for patients across Europe.
A broad solid tumor program investigates KRAS mutation driven cancers and other biomarker‑defined subsets, integrating genomic profiling to guide early‑phase studies such as the MK‑1084 trial.
As Poland’s national oncology institute, the center supports a multidisciplinary team of 55 investigators dedicated to cutting‑edge cancer research.
Clinical trials currently enrolling participants at this site.
PolandA study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer
PolandStudy of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.
PolandStudy of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
PolandStudy of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer
PolandA study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors
PolandA Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer
PolandStudy of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread
PolandStudy of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease
PolandStudy on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer
PolandStudy on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials
PolandStudy of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
PolandMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
